In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nycomed Amersham Imaging

This article was originally published in The Gray Sheet

Executive Summary

Firm commences Phase I clinical trial of lung imaging agent NC100182 to document safety following investigational new drug approval. Based on "spin signal" technology, the firm "is hopeful that potential applications will include use in patients with asthma, cystic fibrosis, chronic obstructive lung disease such as emphysema and patients undergoing transplantation and lung volume reduction surgery." The technology was derived in part through the acquisition of Magnetic Imaging Technologies last year. The Phase I trial is expected to close in the fall and a Phase II trial examining the agent could begin in early 2001

You may also be interested in...



Teva Emerges From Restructuring Ready To Grow

Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.

Executives On The Move: Eisai Taps Celgene And Sanofi VPs For Its Team, And Freeline Selects A CEO

Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.

Triptan Switches Offer Hope For Australia’s OTC Market

Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.
UsernamePublicRestriction

Register

MT013791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel